Business
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
TSX Exchange Symbol: RVX Additional quarterly and clinical updates included CALGARY, Aug. 25 /CNW...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nTSX Exchange Symbol: RVX\n\nAdditional quarterly and clinical updates included\n\n\nCALGARY, Aug. 25 /CNW/ - Resverlogix Corp. (TSX:RVX) is pleased to\nannounce several quarterly updates. The Phase 1b/2a study testing RVX-208 for\n28 days in three different doses has met its primary endpoint of increasing\nplasma ApoA-I significantly. Quality controls are still ongoing as part of\nregular good clinical practice, thus the compilation of the full data report\nshould take place within the second half of 2009. As such if there are\nmodifications to this endpoint they will be communicated. This successful\ndata, in combination with the drug showing favorable safety and tolerance\ncharacteristics, is expected to see RVX-208 progress into Phase 2 studies in\ncardiovascular disease patients.\n\n\nApoA-I is the core protein of HDL, often termed the good cholesterol, and\nApoA-I is generally endorsed as a key protective factor against\natherosclerosis and cardiovascular disease. Developing small molecules\nincreasing ApoA-I would satisfy a huge unmet medical need. This selective\nearly analysis will be communicated in private meetings at the European\nSociety of Cardiology starting at the end of this month. The plasma ApoA-I\nincrease is significant during treatment and at the lowest dose, while\ncontinued increases follow a dose-response and time-response pattern. This\ndata is building on similar results from non-human primate studies and a\nprevious 7-day study in humans last year that also showed significant ApoA-I\nincreases. The safety data has not yet been compiled according to who received\nactive or placebo treatment, nevertheless, based on the number and degree of\nadverse events in total, safety blood analysis and conduct of the study it can\nbe concluded that RVX-208 is safe and tolerable at doses efficient in\nincreasing plasma ApoA-I concentrations.\n\n\nA protocol is being been compiled together with the IVUS Steering\nCommittee including Drs. Nissen, Nicholls, Ballantyne, Taylor, and Kastelein\nfor a Phase 2 study in cardiovascular disease patients which will be discussed\nin conjunction with the 2009 European Society of Cardiology Congress meeting\nin Barcelona, Spain. Resverlogix will be attending this important\ncardiovascular meeting and will communicate the results of the 28 day study to\npotential partners in...